Akorn's $30M Investor Deal Over Failed Merger Gets 1st OK

Law360 (August 26, 2019, 5:04 PM EDT) -- An Illinois federal judge granted preliminary approval on Monday to a settlement that would provide Akorn Inc.'s investors $30 million in cash and resolve claims that the drugmaker's misconduct sunk a multibillion-dollar merger.

U.S. District Judge Matthew F. Kennelly's order certifies a settlement class of investors who purchased Akorn stock between Nov. 3, 2016, and Jan. 8, 2019, the time period during which Akorn is alleged to have lied about information submitted to the U.S. Food and Drug Administration that hid "widespread and systemic data integrity problems" in an attempt to sell the company to German pharmaceutical company Fresenius Kabi AG....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS